实验动物科学 ›› 2026, Vol. 43 ›› Issue (4): 70-78.DOI: 10.3969/ j. issn.1006-6179.2026.04.011

• 论著 • 上一篇    下一篇

盐酸阿霉素纳米制剂联合香菇多糖对三阴性乳腺癌4T1荷瘤小鼠药效研究

  

  1. (1.山西省中医药研究院 (山西省中医院),太原 030012)(2.浙江工业大学药学院,杭州 310014) (3.山西医科大学实验动物中心,太原 030001)(4.江苏省中医药研究院,南京 210028)
  • 收稿日期:2025-08-04 出版日期:2026-08-28 发布日期:2026-09-07
  • 通讯作者: 唐 岚(1974—),女,副教授,研究方向为中药新剂型、新技术研究。E-mail: tanglan@zjut.edu.cn。 张振海(1974—),男,研究员,研究方向为中药制剂新技术。E-mail: david23932@163.com。
  • 作者简介:高 炎(1996—),男,药师,研究方向为中药新剂型及药理研究。E-mail: gaoyantcm@163.com。

Evaluating the Efficacy of Doxorubicin Hydrochloride Nanoparticles in Combination with Lentinan for the Treatment of Triple-Negative Breast Cancer in 4T1 Tumor-Bearing Mice

  1. (1.Shanxi Province Academy of Traditional Chinese Medicine (Shanxi Provincial Hospital of Traditional Chinese Medicine), Taiyuan 030012, China)(2. College of Pharmacy,Zhejiang University of Technology,Hangzhou 310014,China) (3. Laboratory Animal Center of Shanxi Medical University,Taiyuan 030001,China) (4. Jiangsu Provincial Academy of Traditional Chinese Medicine, Nanjing 210028, China)
  • Received:2025-08-04 Online:2026-08-28 Published:2026-09-07

摘要: 目的 研究盐酸阿霉素细胞膜仿生纳米粒(DOX-CM-NPs)、盐酸阿霉素脂质体(DOX-Lips)联合香菇多糖 (LNT)给药后对 4T1 荷瘤小鼠肿瘤生长抑制的药理作用。方法 建立 4T1 乳腺癌小鼠肿瘤模型,将荷瘤小鼠分为 0.9%氯化钠注射液组、DOX·HCl组、DOX-Lips组、DOX-CM-NPs组、LNT组、DOX·HCl+LNT组、DOX-Lips+LNT组、 DOX-CM-NPs+LNT组,每组6只。DOX·HCl、DOX-Lips和DOX-CM-NPs给药剂量统一设定为2 mg/kg,给药剂量以 制剂所载盐酸阿霉素的量进行折算,给药方式为尾静脉注射,给药体积为0.2 mL/只,每隔两天给药1次。香菇多 糖片混悬液的给药浓度为0.2 g/kg,给药方式为灌胃给药,给药体积为0.2 mL/只,每天给药1次,进行体内药效学 和毒性初步评价,采用ELISA法评价免疫调节作用。结果 DOX-CM-NPs组对4T1荷瘤鼠肿瘤的抑制效果显著优 于0.9%氯化钠注射组(P<0.001)、DOX·HCl组(P<0.01)和 DOX-Lips组(P<0.01),并且联合 LNT 给药后抑制效 果进一步加强,且具有协同增效的作用;毒性初步评价和免疫调节作用评价表明,LNT可以通过显著上调白细胞介 素2(IL-2)(P<0.05)、干扰素(IFN-γ)(P<0.01)表达,降低肿瘤坏死因子(TNF-α)(P<0.01)表达,调节免疫功能。 结论 在体内药效研究中,DOX-CM-NPs抑瘤效果强于DOX·HCl和DOX-Lips,联合LNT给药后对4T1荷瘤小鼠治 疗具有协同增效作用。

关键词: 盐酸阿霉素细胞膜仿生纳米粒, 盐酸阿霉素脂质体, 香菇多糖, 乳腺癌, 联合用药

Abstract: Objective To study the inhibition of tumor growth in 4T1 tumor-bearing mice after administration of doxorubicin hydrochloride cell membrane biomimetic nanoparticles (DOX-CM-NPs), doxorubicin hydrochloride liposomes (DOX-Lips) combined with lentinan (LNT) pharmacological effects.Methods A 4T1 breast cancer mouse tumor model was established, and the tumor-bearing mice were divided into 0.9% sodium chloride solution group, DOX·HCl group, DOX-Lips group, DOX-CM NPs group, LNT group, DOX·HCl+LNT group, and DOX- Lips+LNT group, DOX-CM-NPs+LNT group, 6 mice per group. The administration doses of DOX·HCl, DOX-Lips and DOX-CM-NPs were calculated as equivalent DOX·HCl at 2 mg/kg. The administration method was tail vein injection. The administration volume was 0.2 mL/animal and was administered once every two days. The dosage concentration of lentinan tablet suspension is 0.2 g/kg, the dosage method was intragastric administration, the dosage volume was 0.2 mL/animal, and it was administered once a day. Preliminary evaluation of pharmacodynamics and toxicity in vivo is carried out. The immunomodulatory effect was evaluated by ELISA method.Results The inhibitory effect of DOX-CM-NPs on 4T1 tumor-bearing mice was significantly better than that of the physiological 0.9% sodium chloride solution group (P<0.001), the DOX·HCl group (P<0.01) and the DOX-Lips group (P<0.01), and combined with LNT. The inhibitory effect is further strengthened after treatment and has a synergistic effect; preliminary evaluation of toxicity and immunomodulatory effect indicate that LNT It can be regulated by significantly up regulating the expression of interleukin-2 (IL-2) (P<0.05) and interferon (IFN-γ) (P<0.01) and reducing the expression of tumor necrosis factor (TNF-α) (P<0.01). Conclusion In vivo drug efficacy study, DOX-CM-NPs have a stronger tumor-inhibiting effect than DOX·HCl and DOX-Lips, and it has a synergistic effect on the treatment of 4T1 tumor-bearing mice after combined with LNT.

Key words: doxorubicin hydrochloride cell membrane biomimetic nanoparticles, doxorubicin hydrochloride liposomes, lentinan, breast cancer, combination medication

中图分类号: